Investigating the possible therapeutic effects of the homoeopathic remedy Apis Mellifica on Weaver Fish stings using a double blind randomised controlled trial

ISRCTN	ISRCTN16880978
DOI	https://doi.org/10.1186/ISRCTN16880978
Secondary identifying numbers	2005-005934-11

Submission date: 21/12/2005
Registration date: 21/12/2005
Last edited: 06/09/2016

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Injury, Occupational Diseases, Poisoning

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Mr David Retford
Scientific

Opie Building
Trevenson Road
Pool, Redruth
TR15 3RD
United Kingdom

Phone	+44 (0)1209 617620
Email	david.retford@cbs.ac.uk

Study information

Study design	Double Blind Randomised Controlled Trial (RCT)
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	Not specified
Study type	Treatment
Participant information sheet	No participant information sheet available
Scientific title	Investigating the possible Therapeutic Effects of the Homoeopathic Remedy Apis Mellifica on Weaver Fish Stings using a Double Blind Randomised Controlled Trial
Study acronym	Weaver-fish & Homoeopathy
Study objectives	That homoeopathic apis mellificia will be more effective in treating the sting from a weaver fish than a placebo
Ethics approval(s)	Informed consent: understanding spoken and written english, over the age of eighteen, or with parental guidance and consent if under 18. There will be written informed consent from all participants or parents where needed. Informed of data protection, and possible adverse reactions to the homoeopathic remedy. Openness and honesty: Double blind test, thus the participant might be given a placebo although they will still receive the standard treatment. Right to withdraw. Protection from possible harm. Debriefing. Confidentiality and to follow all ethical principals of relevent professional bodies.
Health condition(s) or problem(s) studied	Sting from weaver fish
Intervention	Standard treatment of feet submerged in hot water, plus homoeopathic remedy or placebo remedy
Intervention type	Drug
Pharmaceutical study type(s)
Phase	Not Specified
Drug / device / biological / vaccine name(s)	Apis Mellifica
Primary outcome measure	Pain relief
Secondary outcome measures	Removal of concomitant symptoms
Overall study start date	01/03/2006
Completion date	31/10/2006

Eligibility

Participant type(s)	Patient
Age group	Not Specified
Sex	All
Target number of participants	250
Key inclusion criteria	Type 1, healthy clients, affected by weaver-fish sting, within one hour.
Key exclusion criteria	1. Over 65 years of age 2. Unable to read english 3. Taking any prescribed medication 4. Not NHS registered 5. Have taken any previous form of treatment for the sting 6. Have been stung already this year 7. Any heart condition 8. Any other contraindications to treatment
Date of first enrolment	01/03/2006
Date of final enrolment	31/10/2006

Locations

Countries of recruitment

England
United Kingdom

Study participating centre

Opie Building

Pool, Redruth
TR15 3RD
United Kingdom

Sponsor information

Cornwall College Camborne (UK)
University/education

Opie Building
Trevenson Road
Pool, Redruth
TR15 3RD
England
United Kingdom

Phone	+44 (0)1209 617620
Email	david.retford@cbs.ac.uk
Website	http://www.cornwall.ac.uk/
"ROR"	https://ror.org/006pak935

Funders

Funder type

University/education

Cornwall College Camborne (UK)

No information available

Royal National Lifeboat Institution (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan

Editorial Notes

06/09/2016: No publications found in PubMed, verifying study status with principal investigator.